HealthQuill Dupixent
Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate of worsening episodes in adults with moderate-to-severe asthma, according to a statement.
Drugs Health Pharma

Sanofi’s test drug to treat moderate-to-severe asthma fails to meet goals 

HQ Team April 17, 2025: Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.

Read More
The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease, according to a company statement.
Drugs Health Pharma

EMA approves Sanofi’s treatment for obstructive pulmonary disease

The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary.

Read More